Literature DB >> 26195948

Diagnostic and Prognostic Significance of Serum and Tissue Galectin 3 Expression in Patients with Carcinoma of the Bladder.

Hoda El Gendy1, Bothina Madkour2, Sara Abdelaty2, Fayza Essawy2, Dina Khattab1, Olfat Hammam3, Hani H Nour4.   

Abstract

BACKGROUND: Galectins are group of proteins found in the cytoplasm, nucleus, cell surface and extracellular matrix. Galectin 3 (Gal-3) displays pathological expression in a variety of processes such as tumorigenesis. PATIENTS AND
METHOD: 70 patients classified into the control group, cystitis group, transitional cell carcinoma group, and squamous cell carcinoma group were enrolled in this study which aimed to detect the serum level and the intensity of tissue expression of Gal-3.
RESULTS: Both serum level and tissue expression of Gal-3 were statistically higher in bladder cancer patients compared to the other groups. Gal-3 level expression increased from low to high grade urothelial tumors, with a statistically significant increase of its level and expression between muscle invasive and non-muscle invasive Ta urothelial tumors.
CONCLUSION: The serum Gal-3 level is sensitive and specific for the diagnosis of bladder cancer. The prognostic significance of tissue expression is to be confirmed.

Entities:  

Keywords:  Bladder cancer; Galectin 3; Schistosomiasis; Squamous cell carcinoma; Transitional cell carcinoma

Year:  2014        PMID: 26195948      PMCID: PMC4483295          DOI: 10.1159/000365673

Source DB:  PubMed          Journal:  Curr Urol        ISSN: 1661-7649


  21 in total

Review 1.  Galectin-3 as a multifunctional protein.

Authors:  Anna Krześlak; Anna Lipińska
Journal:  Cell Mol Biol Lett       Date:  2004       Impact factor: 5.787

2.  CA19.9 and CEA in transitional cell carcinoma of the bladder: serological and immunohistochemical findings.

Authors:  Axel Hegele; Verena Mecklenburg; Zoltan Varga; Peter Olbert; Rainer Hofmann; Peter Barth
Journal:  Anticancer Res       Date:  2010-12       Impact factor: 2.480

3.  [Galectin expression in urological cancer. Diagnostic, prognostic and therapeutic potential].

Authors:  S Waalkes; A S Merseburger; A Simon; J Serth; M A Kuczyk
Journal:  Urologe A       Date:  2010-03       Impact factor: 0.639

4.  Galectin-3 expression is associated with bladder cancer progression and clinical outcome.

Authors:  Giacomo Canesin; Pilar Gonzalez-Peramato; Joan Palou; Manuel Urrutia; Carlos Cordón-Cardo; Marta Sánchez-Carbayo
Journal:  Tumour Biol       Date:  2010-04-17

5.  UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer.

Authors:  Paula M J Moonen; Gerard F M Merkx; Pim Peelen; Herbert F M Karthaus; Dominique F C M Smeets; J Alfred Witjes
Journal:  Eur Urol       Date:  2006-10-30       Impact factor: 20.096

6.  Bilharziasis and bladder cancer: a time trend analysis of 9843 patients.

Authors:  Iman Gouda; Nadia Mokhtar; Dalia Bilal; Tarek El-Bolkainy; Nabil M El-Bolkainy
Journal:  J Egypt Natl Canc Inst       Date:  2007-06

Review 7.  Potential new urinary markers in the early detection of bladder cancer.

Authors:  Samir P Shirodkar; Vinata B Lokeshwar
Journal:  Curr Opin Urol       Date:  2009-09       Impact factor: 2.309

8.  Serum level of galectin-3 in human bladder cancer.

Authors:  Manabu Sakaki; Natsuo Oka; Ryoichi Nakanishi; Kunihisa Yamaguchi; Tomoharu Fukumori; Hiro-Omi Kanayama
Journal:  J Med Invest       Date:  2008-02

9.  Galectins as cancer biomarkers.

Authors:  Vitaly Balan; Pratima Nangia-Makker; Avraham Raz
Journal:  Cancers (Basel)       Date:  2010-04-20       Impact factor: 6.639

10.  Regulation of tumor progression by extracellular galectin-3.

Authors:  Pratima Nangia-Makker; Vitaly Balan; Avraham Raz
Journal:  Cancer Microenviron       Date:  2008-02-20
View more
  8 in total

1.  Predictive importance of galectin-3 for recurrence of non-small cell lung cancer.

Authors:  Yoko Kataoka; Tomoyuki Igarashi; Yasuhiko Ohshio; Takuya Fujita; Jun Hanaoka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-03-22

2.  Targeted disruption of galectin 3 in mice delays the first wave of spermatogenesis and increases germ cell apoptosis.

Authors:  Tao Lei; Sandra M Blois; Nancy Freitag; Martin Bergmann; Sudhanshu Bhushan; Eva Wahle; Annie Chi-Chun Huang; Hung-Lin Chen; Michaela F Hartmann; Stefan A Wudy; Fu-Tong Liu; Andreas Meinhardt; Monika Fijak
Journal:  Cell Mol Life Sci       Date:  2021-01-28       Impact factor: 9.261

3.  Co-expression of galectin-3 and CRIP-1 in endometrial cancer: prognostic value and patient survival.

Authors:  Maria Lambropoulou; Theodora-Eleftheria Deftereou; Sryridon Kynigopoulos; Anargyros Patsias; Constantinos Anagnostopoulos; Georgios Alexiadis; Athanasia Kotini; Alexandra Tsaroucha; Christina Nikolaidou; Anastasia Kiziridou; Nikolaos Papadopoulos; Ekaterini Chatzaki
Journal:  Med Oncol       Date:  2015-12-26       Impact factor: 3.064

Review 4.  Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).

Authors:  Rui Dong; Min Zhang; Qunying Hu; Shan Zheng; Andrew Soh; Yijie Zheng; Hui Yuan
Journal:  Int J Mol Med       Date:  2017-12-05       Impact factor: 4.101

Review 5.  Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?

Authors:  Rita Azevedo; Andreia Peixoto; Cristiana Gaiteiro; Elisabete Fernandes; Manuel Neves; Luís Lima; Lúcio Lara Santos; José Alexandre Ferreira
Journal:  Oncotarget       Date:  2017-07-21

6.  Clinical significance of galectin-3 expression in malformed hepatic venous tissue.

Authors:  Junbo Qiao; Yongwei Chen; Changxian Dong; Jin Li
Journal:  Indian J Med Res       Date:  2018-12       Impact factor: 2.375

7.  LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages.

Authors:  Wan-Ming Hu; Yuan-Zhong Yang; Tian-Zhi Zhang; Chang-Fei Qin; Xue-Nong Li
Journal:  Front Med (Lausanne)       Date:  2020-05-21

8.  The clinical significance of HER2 protein amplification/expression in urinary bladder lesion.

Authors:  Olfat Hammam; Hani H Nour; Maha Mosaad; Maha Akl; Heba Khalil; Hossam Al Ganzory; Ali Hindawi
Journal:  Arab J Urol       Date:  2015-03-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.